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Data frommultiple genome-wide association studies are often analyzed together for the purposes of combining information from several
studies of the same disease or comparing results across different disorders. We provide a valid and efﬁcient approach to such meta-anal-
ysis, allowing for overlapping study subjects. The available data may contain individual participant records or only meta-analytic
summary results. Simulation studies demonstrate that failure to account for overlapping subjects can greatly inﬂate type I error when
combining results from multiple studies of the same disease and can drastically reduce power when comparing results across different
disorders. In addition, the proposed approach can be substantially more powerful than the simple approach of splitting the overlapping
subjects among studies, especially for comparing results across different disorders. The advantages of the new approach are illustrated
with empirical data from two sets of genome-wide association studies.Introduction
In the relatively brief but highly informative history of
genome-wide association studies (GWAS),1 meta-analysis
(of individual participant data or summary results) has
proven to be a crucial step. In many instances, the results
of individual studies were unremarkable, and statistically
compelling ﬁndings only emerged after aggressive data
sharing. An excellent model is the discovery of risk loci
for type 2 diabetes (MIM 125853).2–5 Recognizing the
need and beneﬁts of data sharing, GWAS investigators
have formed a large number of consortia and networks.
Several papers have addressed statistical issues in the
meta-analysis of GWAS data.6–9
One important issue in GWAS meta-analysis that has
received little attention is the overlap of study subjects,
i.e., the appearance of the same subjects in multiple
studies. The GWAS requirement for historically large
samples—and its considerable expense—makes it desirable
for individual studies to share control samples. This can
occur by design, as with the Wellcome Trust Case Control
Consortium (WTCCC),10 which genotyped ~2000 cases
from each of seven diseases and ~3000 shared controls
and thus essentially consisted of seven case-control studies
with the same collection of controls. It can also occur
when there is a paucity of available controls. For example,
many psychiatric GWAS conducted in the United States
have used controls ascertained and sampled by P.V. Gej-
man,11 which are commonly referred to as the NIMH
Gejman controls. The problem of overlapping controls
will become more prominent as an increasing number of
case-control studies are taking advantage of publicly avail-
able genotype data for large sets of population-based
controls, such as the WTCCC and Gejman controls. There
are also studies with overlapping cases, although such
overlap tends to be less severe.862 The American Journal of Human Genetics 85, 862–872, DecembA simple approach to dealing with the problem of over-
lapping subjects is to split them among the studies such
that each subject contributes only one record to meta-
analysis. Unfortunately, this seemingly sensible approach
has several drawbacks. First, there is a potential loss of
efﬁciency, especially in cross-disorder comparisons (i.e.,
comparing results across different disorders). Second,
there is generally no unique way to split the overlapping
subjects, and the results of meta-analysis may depend
appreciably on how the overlapping subjects are split.
Third, splitting the overlapping subjects may exacerbate
the bias caused by genotyping errors, as elaborated below.
Fourth, splitting requires access to individual participant
data, which may not be feasible in meta-analysis of
summary results.
A more satisfactory approach is to use all of the records
from all of the studies. This approach maximizes statistical
efﬁciency, produces unique analysis results, and tends to
be less affected by genotyping errors than the approach
of splitting the overlapping subjects. (If an equal number
of cases and controls are randomized to each genotyping
plate, then the genotyping errors will tend to cancel out
between the case and control groups. Splitting control
samples will create unequal numbers of cases and controls
on the plates such that the genotyping errors will not
cancel out between the case and control groups if the
directions or the magnitudes of the errors vary among
the plates.) However, it is necessary to account for the
fact that the observations from the overlapping subjects
are not independent among studies. Failure to do so will
inﬂate type I error when combining information from
multiple studies of the same disease and reduce power
when comparing results across different disorders, as will
be demonstrated in this article.
In this article, we show how to properly adjust for the
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all records are used in meta-analysis. The available data
may consist of individual participant data (i.e., original
phenotype, genotype, and covariate data) or meta-analytic
summary results (i.e., parameter estimates and variance
estimates). (Meta-analysis of individual participant data
has been referred to as mega-analysis and joint analysis.)
We demonstrate through simulation studies that the pro-
posed approach preserves type I error and can be substan-
tially more powerful than the approach of splitting the
overlapping subjects, especially in cross-disorder compari-
sons. Formeta-analysis of a single disorder, careful splitting
of control samples yields statistical power similar to the
proposed approach but still suffers from the bias caused
by genotyping errors and the inherent variability of results.
We evaluate various approaches with empirical data from
the WTCCC study10 and the Genetic Association Informa-
tion Network (GAIN)11 and Clinical Antipsychotic Trials in
Intervention Effectiveness (CATIE)12 schizophrenia (MIM
181500) studies.
Material and Methods
Meta-Analysis of Individual Participant Data
Let Y denote the disease status (1 ¼ disease, 0 ¼ no disease) and
X denote a set of explanatory variables. The explanatory variables
represent the genotype score (or scores) of one or several SNPs and
may also include covariates. Under the commonly used additive
mode of inheritance, the genotype score is the number of minor
alleles; under the dominant (or recessive) model, the genotype
score indicates, by the values 1 versus 0, whether or not the subject
has at least one minor allele (or two minor alleles). (All numerical
results reported in this article are based on the additivemodel.) For
an untyped SNP, the unknown genotype score may be replaced by
the imputed genotype score. The covariates may include environ-
mental factors and the principal components used to adjust for
population stratiﬁcation. It is natural to assume the following
logistic regression model:
PrðY ¼ 1 jXÞ ¼ e
aþbTX
1þ eaþbTX; (Equation 1)
where a is the intercept and b is a set of regression parameters on
the log odds ratio scale.
All meta-analysis problems can be formulated through Equation
1. If we are interested in combining data from two case-control
studies so as to make inference on a common genetic effect
(without adjusting for covariates), then we simply set X ¼
(G, S)T, whereG is the genotype score and S indicates, by the values
1 versus 0, whether the subject is from the ﬁrst study; the regres-
sion parameter associated with G is the log odds ratio for the
common genetic effect, whereas the regression parameter associ-
ated with S reﬂects the difference of the case-control ratios
between the two studies. If we wish to compare the genetic effects
between the two studies, then we deﬁne X ¼ (G, S, G*S)T, and the
regression parameter associated with G*S is the difference of the
log odds ratios between the two studies. It is straightforward to
extend the formulation to more than two studies and to incorpo-
rate covariates into Equation 1.
Suppose that there is a total of n study subjects, counting the
subjects as many times as they appear in the studies. ForThe Americai ¼ 1, ., n, let Yi and Xi denote the values of Y and X on the ith
subject. Let q denote the collection of a and b. The ‘‘likelihood’’
for q takes the form
LðqÞ ¼
Yn
i¼1
eYiðaþb
TXiÞ
1þ eaþbTXi :
The corresponding ‘‘score function’’ and ‘‘information matrix’’ are
UðqÞ ¼
Xn
i¼1
 
Yi  e
aþbTXi
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1
Xi

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,
respectively. The ‘‘maximum likelihood estimator’’ q^ is the maxi-
mizer of L(q) or equivalently the solution to the estimating equa-
tion U(q) ¼ 0.
We use the quotationmarks for the likelihood and related quan-
tities because L(q) is not the correct likelihood when study subjects
overlap. Although q^ is not a genuine maximum likelihood esti-
mator, we show in the Appendix that q^ is a valid estimator of q
and that its variance can be estimated properly from the data.
Speciﬁcally, q^ is approximately normal with mean q and vari-
ance-covariance matrix
V

q^
 ¼ I1q^Iq^þDq^I1q^, (Equation 2)
where
DðqÞ ¼
Xn
i¼1
Xn
j¼1
dijUiðqÞUjðqÞT,
Ui(q) is the ith summand inU(q), and dij takes the value 1 if is j but
the ith and jth subjects are the same subject and takes the value
0 otherwise. If there are no overlapping subjects, then D(q) ¼ 0,
so Vðq^Þ reduces to I1ðq^Þ, which is the usual variance-covariance
estimator of the maximum likelihood estimator.
We will refer to the approach described above as ‘‘sharing
subjects,’’ in that all overlapping subjects are included in the
meta-analysis as many times as they appeared in the studies.
This is in contrast to the approach of ‘‘splitting subjects,’’ in which
the overlapping subjects are divided among the studies such that
every subject is used only once in the meta-analysis. We will refer
toVðq^Þ and I1ðq^Þ as the robust and naive variance-covariance esti-
mators, respectively, in that the former properly accounts for the
correlation of the observations from the same subject whereas
the latter does not. Clearly, V(q) ¼ I1(q) þ I1(q)D(q)I1(q), so
I1(q)D(q)I1(q) is the extra variance due to overlap.
Meta-Analysis of Summary Results
Suppose that there are K studies with potentially overlapping
subjects. For k ¼ 1, ., K, let h^k be the estimator of a common
genetic effect h from the kth study and let Vk be the corresponding
variance estimator. For meta-analysis of K independent studies
with such summary results, the well-known inverse-variance esti-
mator of h is
h^ ¼
XK
k¼1
wkh^k, (Equation 3)
where wk ¼ V1k =
PK
k¼1 V
1
k ; the variance of h^ is estimated byPK
k¼1 w
2
kVk. When study subjects overlap, the optimal weightsn Journal of Human Genetics 85, 862–872, December 11, 2009 863
are no longer proportional to the inverse variances, and the vari-
ance of h^ is no longer
PK
k¼1 w
2
kVk. It can be shown that the optimal
weights are
½w1,. wK ¼ eTU1=eTU1e, (Equation 4)
where e is a K 3 1 vector of 1’s and U is the (estimated) covariance
matrix of ðh^1;.; h^KÞ.13 Regardless of what thewks are, the variance
of h^ takes the form
Var

h^
 ¼XK
k¼1
w2kVk þ 2
XK
k¼1
XK
l¼kþ1
wkwlCov

h^k,h^l

, (Equation 5)
where Cov denotes covariance. For cross-disorder comparisons,
the difference between the genetic effects of the kth and lth studies
is simply estimated by h^k  h^l, and the corresponding variance is
Var

h^k  h^l
 ¼ Vk þ Vl  2Covh^k,h^l: (Equation 6)
It is evident from Equation 5 and Equation 6 that failure to
account for overlapping subjects will underestimate the true vari-
ation whenmaking inference on a common genetic effect and will
overestimate the true variation when comparing genetic effects
across studies.We will refer to Equation 5 and Equation 6 as robust
variance estimators in that they properly account for the correla-
tions of the overlapping subjects.
To carry out the aforementioned analyses, we need to estimate
the covariances or correlations of the h^ks. We derive in the
Appendix a simple correlation formula for case-control studies:
Corr

h^k,h^l

z

nkl0
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
nk1nl1
nk0nl0
r
þ nkl1
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
nk0nl0
nk1nl1
r 
 ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
nknl
p
, (Equation 7)
where nk1, nk0, and nk (or nl1, nl0, and nl) are, respectively, the
number of cases, the number of controls, and the total number
of subjects in the kth (or lth) study and nkl0 and nkl1 are, respec-
tively, the numbers of controls and cases that overlap between
the kth and lth studies. This formula also applies to the score tests.
The approximation is accurate if the case-control status is inde-
pendent of all explanatory variables in the model, which is true
under the null hypothesis of no genetic association when no cova-
riates are included in the analysis. The approximation may be
inaccurate in the presence of strong genetic and/or covariate
effects.
Results
Simulation Studies
We conducted simulation studies to compare the perfor-
mance of the robust and naive variance estimators when
sharing the overlapping subjects in the meta-analysis of
individual participant data and to assess the efﬁciency
loss of splitting the overlapping subjects. The ﬁrst set of
simulation studies was focused on combining results
from multiple studies of the same disease. We simulated
n1 cases and n0 controls frommodel 1 (i.e., themodel given
in Equation 1), in which X is the number of minor alleles
of the test SNP. We created two studies with n1/2 cases
each, or with 3n1/4 cases in one study and n1/4 cases in
the other. We considered various combinations of n1 and
n0. For each conﬁguration, we generated 10 million data
sets. Each simulated data set was analyzed in two ways:864 The American Journal of Human Genetics 85, 862–872, Decembsharing all of the n0 controls between the two studies,
and splitting the control samples between the two studies
in a 1:1, 3:1, or 1:3 ratio. In either approach, we ﬁt model 1
in which X consists of the genotype score (i.e., the number
of minor alleles) and the study indicator, and we tested the
null hypothesis that b ¼ 0. The results reported below
pertain to the choices of a ¼ 3, b ¼ 0 or 0.3, minor allele
frequency (MAF) of 0.3, and nominal signiﬁcance levels of
104 and 107 under b ¼ 0 and b ¼ 0.3, respectively. The
results are similar for other choices of a, MAF, and nominal
signiﬁcance levels. Note that b ¼ 0 and 0.3 correspond to
odds ratios of 1 and ~1.35.
The type I error rates of the joint association tests when
the control samples are shared between the two studies
are shown in Table 1 under the heading ‘‘Original Data.’’
Because the robust variance estimator accurately reﬂects
the true variation of the odds ratio estimator (data not
shown), the corresponding association test has proper
type I error. (The slight conservativeness is a general
phenomenon for Wald tests at extreme nominal signiﬁ-
cance levels and not a unique feature of the proposed
method.) By contrast, the naive variance estimator seri-
ously underestimates the true variation (data not shown),
so the corresponding association test has grossly inﬂated
type I error, especially under the ﬁrst and ﬁfth scenarios.
The reason that the inﬂation of the type I error for the naive
method decreases as the number of controls increases is
because it can be shown from Equation 2 that the extra
variance due to overlap is inversely proportional to n0.
The powers of the joint association tests under b ¼ 0.3
when the control samples are shared versus split between
the two studies are shown in Table 2 under the heading
‘‘Original Data.’’ (When the control samples are shared,
the robust variance estimator is used.) When the control
samples are split in the same ratio as the numbers of cases
between the two studies, the two approaches have virtually
the same power. When the control samples are split in
Table 1. Type I Error Rates (3104) of Association Tests at the
Nominal Significance Level of 104 When Control Samples Are
Shared in the Combined Analysis of Two Case-Control Studies
No. of Cases Original Data Summary Results
Study 1 Study 2
No. of
Controls Robusta Naiveb Robusta Naiveb
1000 1000 1000 0.96 14.9 0.97 14.8
1000 1000 2000 0.95 7.4 0.96 7.4
1000 1000 3000 0.93 5.0 0.95 5.0
1000 1000 4000 0.96 3.7 0.96 3.7
1500 500 1000 0.97 11.3 0.96 11.2
1500 500 2000 0.97 5.5 0.96 5.5
1500 500 3000 0.95 3.8 0.94 3.8
1500 500 4000 0.96 2.9 0.97 2.9
a Robust variance estimator used.
b Naive variance estimator used.er 11, 2009
Table 2. Powers of Association Tests at the Nominal Significance Level of 107When Control Samples Are Shared or Split in the Combined
Analysis of Two Case-Control Studies
Original Data Summary Results
No. of Cases Splitting Controls
Study 1 Study 2 No. of Controls Sharing Controlsa 1:1 3:1 1:3 Sharing Controlsa
1000 1000 1000 0.34 0.34 0.28 0.28 0.31
1000 1000 2000 0.73 0.73 0.66 0.66 0.71
1000 1000 3000 0.88 0.88 0.83 0.83 0.87
1000 1000 4000 0.93 0.93 0.90 0.90 0.93
1500 500 1000 0.32 0.28 0.33 0.15 0.31
1500 500 2000 0.72 0.66 0.73 0.43 0.72
1500 500 3000 0.87 0.83 0.88 0.63 0.87
1500 500 4000 0.93 0.90 0.93 0.75 0.93
a Robust variance estimator used.a different ratio, however, sharing is considerably more
powerful than splitting.
The next set of simulation studies was concerned with
the comparison of odds ratios between different studies
(i.e., cross-disorder comparison). We simulated two case-
control studies with a set of common controls, the cases
in the two studies representing two different disorders.
The log odds ratios for the two studies were b1 and b2,
and we were interested in testing the null hypothesis
that b1 ¼ b2. Other than potentially unequal odds ratios
between the two studies, the simulation parameters were
the same as in the ﬁrst set of simulation studies. We set
b1 ¼ b2 ¼ 0.3 under the null hypothesis and b1 ¼ 0 and
b2 ¼ 0.5 under the alternative hypothesis. Note that the
b value of 0.5 corresponds to an odds ratio of ~1.65. Again,
we generated 10 million data sets for each scenario and
analyzed each simulated data set by sharing or splitting
the control samples between the two studies. Whether
the control samples were shared or split, we ﬁt model 1
in which X consists of the genotype score, the study indi-
cator, and their product. (The regression parameter associ-
ated with the product term corresponds to the difference
between the log odds ratios of the two studies.)
The type I error rates for testing the null hypothesis that
b1¼ b2 when the control samples are shared in the analysis
are displayed in Table 3 under the heading ‘‘Original Data.’’
Again, the robust variance estimator accurately reﬂects the
true variation (data not shown) and thus yields proper type
I error. The naive variance estimator overestimates the true
variation (data not shown), so the corresponding test is too
conservative.
The powers against the alternative hypothesis that
b1 ¼ 0 and b2 ¼ 0.5 when the control samples are shared
versus split in the analysis are presented in Table 4 under
the heading ‘‘Original Data.’’ When the control samples
are shared, the use of the robust variance estimator yields
a much more powerful test than the use of the naive vari-
ance estimator. Splitting the control samples results inThe Americasubstantial loss of power, especially when the total number
of controls is small.
An important technical issue in GWAS is the possible
presence of plate effects where there are important (but
undetected) biases in the genotyping of some subjects.
To assess the biases caused by splitting control samples in
the presence of plate effects, we simulated a case-control
study with 1920 cases and 1920 controls (i.e., 3840
subjects on 40 96-well plates) from model 1 with a ¼ 3
and b ¼ 0. We assumed that cases and controls were
randomly assigned such that there was an equal number
of cases and controls on each genotyping plate. We gener-
ated the genotypes for a test SNP with relatively low MAF
independently of the case-control status. For ~n cases and
~n controls, each heterozygous genotype was miscalled as
minor homozygous genotype with probability 0.1, and
eachmajor homozygous genotype wasmiscalled as hetero-
zygous also with probability 0.1. (For a SNP with relatively
Table 3. Type I Error Rates (3104) at the Nominal Significance
Level of 104 for Testing Equal Odds Ratios When Control Samples
Are Shared Between Two Case-Control Studies
No. of Cases Original Data Summary Results
Study 1 Study 2
No. of
Controls Robusta Naiveb Robusta Naiveb
1000 1000 1000 0.95 0.001 1.65 0.001
1000 1000 2000 0.98 0.027 1.36 0.027
1000 1000 3000 0.99 0.091 1.25 0.091
1000 1000 4000 1.00 0.173 1.21 0.173
1500 500 1000 0.92 0.004 1.42 0.004
1500 500 2000 0.93 0.084 1.19 0.084
1500 500 3000 0.93 0.177 1.11 0.177
1500 500 4000 0.94 0.265 1.08 0.265
a Robust variance estimator used.
b Naive variance estimator used.n Journal of Human Genetics 85, 862–872, December 11, 2009 865
Table 4. Powers of Detecting Unequal Odds Ratios at the Nominal Significance Level of 107 When Control Samples Are Shared or Split
between Two Case-Control Studies
Original Data Summary Results
No. of Cases Sharing Controls Splitting Controls Sharing Controls
Study 1 Study 2 No. of Controls Robusta Naiveb 1:1 3:1 1:3 Robusta Naiveb
1000 1000 1000 0.93 0.30 0.11 0.05 0.05 0.95 0.30
1000 1000 2000 0.94 0.67 0.36 0.23 0.24 0.95 0.67
1000 1000 3000 0.94 0.78 0.53 0.40 0.41 0.95 0.78
1000 1000 4000 0.94 0.83 0.64 0.53 0.54 0.95 0.83
1500 500 1000 0.66 0.13 0.06 0.03 0.03 0.72 0.13
1500 500 2000 0.67 0.35 0.19 0.13 0.13 0.70 0.35
1500 500 3000 0.67 0.45 0.30 0.22 0.23 0.70 0.45
1500 500 4000 0.68 0.51 0.37 0.29 0.30 0.69 0.51
a Robust variance estimator used.
b Naive variance estimator used.low MAF, no minor homozygous genotypes may exist on
a plate, so the clustering plots tend to mistakenly assign
some heterozygous genotypes to minor homozygous
genotypes and some major homozygous genotypes to
heterozygous genotypes.) For the remaining ðn ~nÞ cases
and ðn ~nÞ controls, all genotypes were called correctly.
We assumed that the ~n controls with potentially miscalled
genotypes were involved in a second case-control study,
which also randomized cases and controls to each plate.
(If we share the overlapping control samples in the meta-
analysis of such studies, the balance between cases and
controls in each plate ensures that the expected genotype
frequencies are the same between the case and control
groups, which in turn ensures valid association testing. If
we split the overlapping control samples, the resulting
unequal numbers of cases and controls with genotyping
errors within each study will yield unequal genotype
frequencies between the case and control groups, which
will inﬂate type I error.) We simulated 10 million data
sets with ~n ¼ 96, 192, or 384 (i.e., one, two, or four plates)
and MAF ¼ 0.05 or 0.1. Table 5 shows the impact of split-
ting the overlapping control samples between the two
studies on the association testing of the ﬁrst study. When
the overlapping control samples were shared in the anal-
ysis (such that no records were excluded) and the robust
variance estimator was used, the type I error rates of the
association tests were below the nominal signiﬁcance
level. When the overlapping control samples were split
between the two studies such that a portion of the controls
were excluded from the ﬁrst study, the type I error rates
were inﬂated, especially when the number of controls
excluded was large.
All of the above simulation results pertain to the use of
individual participant data. We also assessed the perfor-
mance of the methods for meta-analysis of summary
results. According to Equation 7, the correlation coefﬁ-
cients (between the estimated genetic effects of the two866 The American Journal of Human Genetics 85, 862–872, Decemstudies) for the eight scenarios shown in Tables 1–4 are
0.5, 0.333, 0.25, 0.2, 0.447, 0.293, 0.218, and 0.174. Under
b ¼ 0, the empirical correlation coefﬁcients were found to
be identical to the theoretical values up to the third
decimal point. Under b ¼ 0.3, the empirical correlation
coefﬁcients were estimated at 0.467, 0.307, 0.229, 0.182,
0.416, 0.269, 0.199, and 0.159, all of which are slightly
below the theoretical values. Under b¼0.3, the empirical
correlation coefﬁcients were 0.524, 0.358, 0.273, 0.220,
0.471, 0.316, 0.239, and 0.192, all of which are slightly
above the theoretical values.
The type I error rates and powers for meta-analysis of
summary results are shown in Tables 1–4 under the
heading ‘‘Summary Results.’’ For testing a common genetic
effect, the type I error rates and powers based on summary
results are nearly identical to those of individual partici-
pant data (see Table 1 and Table 2). For testing the equality
of two odds ratios, meta-analysis of summary results based
Table 5. Type I Error Rates (3104) of Association Tests at the
Nominal Significance Level of 104 When Different Proportions of
the Controls with Potential Genotyping Errors Are Excluded
No. of Controls Proportion Excluded MAF ¼ 0.05 MAF ¼ 0.1
96 0 0.81 0.90
1/2 1.26 1.13
1 2.84 1.89
192 0 0.81 0.92
1/2 2.39 1.77
1 13.2 6.18
384 0 0.74 0.81
1/2 7.99 4.34
1 145.0 44.1
MAF denotes minor allele frequency.ber 11, 2009
on the robust variance estimator had slight inﬂation of
type I error and was slightly more powerful than meta-
analysis of individual participant data based on the robust
variance estimator because Equation 7 overestimates the
correlation coefﬁcients when the odds ratios are greater
than 1 (see Table 3 and Table 4). Note that the two odds
ratios were set to ~1.35 under the null hypothesis of equal
odds ratios. Meta-analysis of summary results based on the
robust variance estimator had very accurate control of type
I error when the two odds ratios were set to 1 instead of
1.35 (data not shown).
The last set of simulation studies was designed to assess
the performance of meta-analysis of summary results
when principal components are included in the model to
adjust for population stratiﬁcation. We simulated and
analyzed data in the same way as before, except that the
new model included a normally distributed covariate
whose mean was the genotype score and whose variance
was 1. We found that the actual correlations ﬂuctuated
slightly around the theoretical values determined by Equa-
tion 7 (data not shown). As shown in Table 6, the proposed
method had good control of type I error even when the
covariate effects were unusually strong.
WTCCC Data
We considered GWAS data on rheumatoid arthritis (RA
[MIM 180300]) and type 1 diabetes (T1D [MIM 222100])
from the WTCCC study.10 RA and T1D are both autoim-
mune disorders and are known to share common loci.
The database contains 1860 subjects with RA, 1963 with
T1D, and 2938 common controls. For the meta-analysis,
we viewed the data as two case-control studies, one on
RA and one on T1D, with completely overlapping controls.
The WTCCC reported eight SNPs that are signiﬁcantly
associated with RA, T1D, or both.10 For each of these eight
SNPs, we performed the trend test and estimated the odds
ratio under the additive model for both RA and T1D. The
results are shown in Table 7. The ﬁrst three SNPs areThe Americanstrongly associated with both RA and T1D, although the
odds ratios appear to be quite different between RA and
T1D for the second and third SNPs. The fourth SNP is
more strongly associated with RA than with T1D. The
results for the ﬁfth SNP are almost identical between RA
and T1D. The last three SNPs are signiﬁcantly associated
with T1D, but not with RA. We performed meta-analysis
to formalize these statements.
To combine the results on RA and T1D, we ﬁt model 1 in
which X ¼ (G, S)T, where G is the number of minor alleles
of each SNP and S indicates, by the values 1 versus 0,
whether the subject belongs to the RA case-control study
or the T1D case-control study; the regression parameter
associated with G is the common log odds ratio for RA
and T1D. Thus, this analysis yields an estimate of
a common odds ratio for RA and T1D and an overall trend
test for the association of the SNP with the two diseases.
Table 6. Type I Error Rates (3104) of Association Tests Based on
Equations 4, 5, and 7 at the Nominal Significance Level of 104 in
the Presence of Population Stratification
No. of Cases
Study 1 Study 2
No. of
Controls OR* ¼ 1.35 OR* ¼ 1.65 OR* ¼ 2.23
1000 1000 1000 0.85 0.79 0.73
1000 1000 2000 0.92 0.89 0.89
1000 1000 3000 0.96 0.97 0.96
1000 1000 4000 0.94 1.00 1.04
1500 500 1000 0.88 0.86 0.82
1500 500 2000 0.94 0.93 0.93
1500 500 3000 0.96 0.97 1.01
1500 500 4000 0.95 1.01 1.05
Population stratification is represented by a normal covariate that is correlated
with the genotype score of the test locus and whose odds ratio with the disease
is denoted by OR*. OR* is the increase in the odds of disease for every unit
increase of the covariate value.Table 7. Estimates of Odds Ratios and p Values of Trend Tests for Rheumatoid Arthritis and Type 1 Diabetes in the WTCCC Data
RA T1D
Chr SNP Est SE p Value Est SE p Value
1p13 rs6679677 1.95 0.124 8.9 3 1026 1.89 0.117 5.1 3 1025
6(RA) rs6457617 0.44 0.020 5.5 3 1072 0.71 0.031 2.3 3 1015
6(T1D) rs9272346 0.72 0.032 4.7 3 1014 0.27 0.015 9.1 3 10122
7q32 rs11761231 0.81 0.036 2.4 3 106 0.91 0.039 2.8 3 102
10p15 rs2104286 0.80 0.039 7.1 3 106 0.81 0.038 1.1 3 105
12q13 rs11171739 0.99 0.042 8.6 3 101 1.33 0.055 1.3 3 1011
12q24 rs17696736 1.13 0.048 3.5 3 103 1.39 0.058 3.4 3 1015
16p13 rs12708716 0.97 0.043 4.5 3 101 0.79 0.035 7.4 3 108
The following abbreviations are used: RA, rheumatoid arthritis; T1D, type 1 diabetes; Est, estimate of odds ratio; SE, standard error estimate. p values shown are
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Table 8. Meta-Analysis of Individual Participant Data for Rheumatoid Arthritis and Type 1 Diabetes in the WTCCC Data
Common Odds Ratio Ratio of Odds Ratios
Robusta Naiveb Robusta Naiveb
Chr SNP Est SE p Valuec SE p Valuec Est SE p Valued SE p Valued
1p13 rs6679677 1.92 0.104 2.7 3 1033 0.085 4.6 3 1049 1.03 0.064 6.5 3 101 0.091 7.5 3 101
6(RA) rs6457617 0.56 0.021 5.3 3 1055 0.017 2.0 3 1076 0.62 0.030 4.5 3 1022 0.039 5.6 3 1014
6(T1D) rs9272346 0.47 0.019 6.5 3 1082 0.016 3.3 3 10109 2.61 0.154 6.8 3 1060 0.185 6.6 3 1042
7q32 rs1176123 0.86 0.031 3.6 3 105 0.026 1.1 3 106 0.89 0.043 1.7 3 102 0.055 6.3 3 102
10p15 rs2104286 0.81 0.032 8.5 3 108 0.027 3.4 3 1010 0.99 0.053 8.6 3 101 0.067 8.9 3 101
12q13 rs11171739 1.15 0.040 6.5 3 105 0.034 2.4 3 106 0.75 0.035 3.6 3 1010 0.044 1.0 3 106
12q24 rs17696736 1.26 0.044 7.7 3 1011 0.037 1.5 3 1014 0.81 0.038 9.0 3 106 0.049 5.5 3 104
16p13 rs12708716 0.87 0.032 2.1 3 104 0.027 1.3 3 105 1.23 0.060 3.0 3 105 0.077 1.1 3 103
Common odds ratio represents inference on a common odds ratio; ratio of odds ratios represents comparison of two odds ratios. The following abbreviations are
used: Est, parameter estimate; SE, standard error estimate.
a Robust variance estimator used.
b Naive variance estimator used.
c p value for testing no association.
d p value for testing equal odds ratios.The results are shown in Table 8 under the heading
‘‘Common Odds Ratio.’’ There is strong evidence of associ-
ation for 5 of the 8 SNPs. Because of completely overlap-
ping controls, the naive variance estimator substantially
underestimates the true variation and the corresponding
p values grossly exaggerate the degrees of statistical signi-
ﬁcance.
To compare the strengths of association between RA and
T1D, we ﬁt model 1 in which X ¼ (G, S, G*S)T; the regres-
sion parameter associated with G*S is the difference of
the log odds ratios between RA and T1D. Thus, this anal-
ysis yields an estimate of the ratio of the odds ratios
between RA and T1D and the corresponding test for the
equality of the two odds ratios. The results are shown in
Table 8 under the heading ‘‘Ratio of Odds Ratios.’’ Based
on the robust variance estimator, there is strong evidence
that the effects of SNPs 2, 3, and 6 are different between
RA and T1D, as well as moderate evidence that the effects
of SNPs 7 and 8 are different between the two diseases. For
this analysis, the use of the naive variance estimator
greatly weakens the statistical evidence.
The results in Table 8 were obtained by sharing the
controls in the meta-analysis. Figure 1 contrasts this
approach with the approach of splitting the control
samples in testing the equality of the two odds ratios. For
the latter approach, we split the control samples equally
between RA and T1D with three different random
sequences. Splitting the control samples yields consider-
ably less extreme p values than sharing the control
samples. This phenomenon is consistent with the simula-
tion results of Table 2. For some of the SNPs, the p values
vary appreciably among the three random splits.
We also conducted meta-analysis of the summary results
of Table 7 (pretending no access to individual participant
data). According to Equation 7, the correlation between868 The American Journal of Human Genetics 85, 862–872, Decembthe genetic effects for RA and T1D is approximately
0.394. Given this correlation estimate, we used Equations
3–6 to perform the meta-analysis of summary results.
The ﬁndings are reported in Table 9. The estimates of the
common odds ratios and the corresponding standard error
estimates are extremely close to their counterparts in
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Figure 1. p Values for Testing Equality of Odds Ratios between
Rheumatoid Arthritis and Type 1 Diabetes in the WTCCC Data
When the Control Samples Are Shared or Split in the Analysis
The robust variance estimator is used when the control samples
are shared in the analysis; three different random sequences are
used to split the control samples. RA indicates rheumatoid
arthritis; T1D indicates type 1 diabetes.er 11, 2009
Table 9. Meta-Analysis of Summary Results for Rheumatoid Arthritis and Type 1 Diabetes in the WTCCC Data
Common Odds Ratio Ratio of Odds Ratios
Robusta Naiveb Robusta Naiveb
Chr SNP Est SE p Valuec Est SE p Valuec Est SE p Valued SE p Valued
1p13 rs6679677 1.92 0.100 1.1 3 1035 1.92 0.085 4.5 3 1049 1.03 0.071 6.8 3 101 0.091 7.5 3 101
6 (RA) rs6457617 0.57 0.021 7.2 3 1052 0.57 0.018 2.3 3 1073 0.62 0.030 4.8 3 1022 0.039 5.6 3 1014
6(T1D) rs9272346 0.52 0.021 2.1 3 1057 0.49 0.017 4.2 3 1094 2.61 0.145 5.3 3 1067 0.185 6.6 3 1042
7q32 rs1176123 0.86 0.031 4.5 3 105 0.86 0.026 1.2 3 106 0.89 0.042 1.7 3 102 0.055 6.3 3 102
10p15 rs2104286 0.81 0.032 1.1 3 107 0.81 0.027 3.4 3 1010 0.99 0.052 8.6 3 101 0.067 8.9 3 101
12q13 rs11171739 1.15 0.040 6.2 3 105 1.15 0.034 2.8 3 106 0.75 0.035 3.5 3 1010 0.044 1.0 3 106
12q24 rs17696736 1.26 0.044 7.4 3 1011 1.26 0.038 1.9 3 1014 0.81 0.038 9.1 3 106 0.049 5.5 3 104
16p13 rs12708716 0.87 0.032 2.4 3 104 0.87 0.027 1.4 3 105 1.23 0.060 2.6 3 105 0.077 1.1 3 103
Common odds ratio represents inference on a common odds ratio; ratio of odds ratios represents comparison of two odds ratios. The following abbreviations are
used: Est, parameter estimate; SE, standard error estimate.
a Robust variance estimator used.
b Naive variance estimator used.
c p value for testing no association.
d p value for testing equal odds ratios.Table 8, except for the third SNP. The estimates of the ratios
of odds ratios are identical to their counterparts of Table 8;
the corresponding standard error estimates are very close
to their counterparts of Table 8, except for the ﬁrst and
third SNPs.
Schizophrenia Data
Our work was motivated by the presence of overlapping
subjects in the Psychiatric GWAS Consortium.14 There
are currently 17 schizophrenia studies in the consortium,
with a total of 9387 cases, 12,301 controls, and 588 over-
lapping subjects. For this illustration, we considered two
schizophrenia studies, the GAIN schizophrenia study11
and the CATIE study,12 and focused on the European-
ancestry samples. There are 415 cases and 407 controls in
the CATIE study and 1396 cases and 1442 controls in the
GAIN study, with 199 controls appearing in both studies.
Although the overlapping controls account for only
~10% of the controls and 5% of all study subjects, the
analysis results may depend appreciably on how the
overlapping controls are handled.
We performed joint association tests for the CATIE and
GAIN studies by sharing the 199 overlapping controls. We
also considered four ways of splitting the overlapping
control samples: (1) assigning all 199 controls to CATIE,
(2) assigning all 199 controls to GAIN, (3) randomly assign-
ing 99 controls to GAIN and 100 to CATIE, or (4) randomly
assigning 29 controls to GAIN and 170 to CATIE. Option 4
yields equal case/control ratios between the two studies and
should be themost efﬁcient. Options 1 and 4 differ only by
29 subjects.Option2deviates themost fromoption4 and is
thus expected to yield the least signiﬁcant results.
Figure 2 displays the p values of the trend tests for seven
SNPs in a 0.4Mb region on chromosome 7. The p values forThe Americansharing the control samples are based on the meta-analysis
of individual participant data, but those of the meta-
analysis of summary results are very similar. Even with
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Figure 2. p Values of Joint Association Tests When the Overlap-
ping Control Samples Are Shared or Split between the CATIE and
GAIN Studies
‘‘Sharing (robust)’’ and ‘‘sharing (naive)’’ pertain to the use of the
robust and naive variance estimators when the overlapping
control samples are shared in the meta-analysis. Under option 1,
all 199 overlapping controls are assigned to CATIE; under option
2, all 199 overlapping controls are assigned to GAIN; under option
3, a total of 99 overlapping controls are randomly assigned to
GAIN and 100 to CATIE; under option 4, a total of 29 overlapping
controls are randomly assigned to GAIN and 170 to CATIE.Journal of Human Genetics 85, 862–872, December 11, 2009 869
5% overlapping subjects, failure to account for correlated
observations can cause considerable inﬂation of statistical
signiﬁcance: the p values based on the naive variance
estimates are appreciably lower than those of the robust
variance estimates. There are some noticeable differences
between splitting control samples and sharing control
samples (with the use of the robust variance estimator).
As expected, the results for options 1 and 4 are very similar,
and option 2 tends to yield the least signiﬁcant results.
Discussion
There is a growing interest in the meta-analysis of GWAS
data for the purposes of combining results from multiple
studies of the same disease or comparing results across
different disorders. It is common for the same subjects to
appear in multiple studies of the same disease or related
disorders. If subject overlap is ignored, the validity and
efﬁciency of meta-analysis can be severely compromised.
Speciﬁcally, there will be inﬂation of type I error in joint
association testing and reduction of power in cross-
disorder comparisons.
We have developed a very general framework to deal
with overlapping subjects in GWAS meta-analysis. Its val-
idity and efﬁciency have been clearly demonstrated with
simulated and empirical data. The proposed approach is
simple to implement and is computationally feasible for
large GWAS. The relevant software is available at our
website.
Our work covers both meta-analysis of individual partic-
ipant data and meta-analysis of summary results. When
there are no overlapping subjects, the two types of anal-
ysis have the same statistical efﬁciency.9 In the presence
of overlapping subjects, the two types of analysis will still
produce similar results, as shown in the Results section.
Given access to individual participant data, one can
account for the correlated observations of overlapping
subjects in a very accurate manner through Equation 2.
The correlation formula for meta-analytic summary results
given in Equation 7 is asymptotically exact when there are
no genetic or covariate effects and is a reasonable approx-
imation even in the presence of strong covariate effects
but may not be accurate when there are strong genetic
effects. Thus, joint association testing of genetic effects
based on this correlation formula is valid in the absence
of covariates and approximately valid in the presence of
covariate effects; however, the cross-disorder comparison
may not have correct type I error if the odds ratios are
equal across different disorders but are far away from 1.
Thus, we recommend the use of Equation 2 when
individual participant data are available and the use of
Equation 7 when only meta-analytic summary results are
available.
It is straightforward to perform meta-analysis of
summary results. The optimal weights given in Equation
4 require special calculations. The usual weights based on870 The American Journal of Human Genetics 85, 862–872, Deceminverse variances can be used instead. The efﬁciency gains
due to the use of the optimal weights depend on the
patterns of overlap among the studies. Regardless of the
choices of the weights, it is important to account for the
correlations of overlapping subjects through Equation 5
and Equation 7; otherwise, the validity of meta-analysis
would be compromised.
Although we have focused our attention on case-control
studies, the proposed approach can be applied to other
types of studies. For a different study design, the regression
model and the ‘‘likelihood’’ and related quantities will be
different. However, the robust variance estimator given in
Equation 2 is applicable to any parametric model as long
as Ui is deﬁned as the contribution of the ith study subject
to the ‘‘score function.’’ For a quantitative trait in a cross-
sectional study satisfying the linear regression model
Yi ¼ aþ bTXi þ 3i,
where 3i is normal with mean 0 and variance s
2, the ‘‘score
function’’ for q ¼ (a, b, s2) is
UðqÞ ¼
2
666666664
1
s2
Sni¼1

Yi  a bTXi

1
s2
Sni¼1

Yi  a bTXi

Xi
1
2s4
Sni¼1

Yi  a bTXi
2 n
2s2
3
777777775
:
If the overlap of subjects occurs completely at random,
then the analog of Equation 7 is
Corr

h^k,h^l

znkl=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
nknl
p
, (Equation 8)
where nk and nl are the numbers of subjects in the kth and
lth studies, respectively, and nkl is the number of overlap-
ping subjects between the kth and lth studies. Unlike the
situation of case-control studies, Equation 8 is accurate
regardless of whether or not there are any genetic or cova-
riate effects. When data on quantitative traits are collected
from case-control rather than cross-sectional studies, the
above formulas are approximately correct if the case-
control status is included as a covariate in the linear
regression.15
For making inference on a common odds ratio, one can
achieve statistical efﬁciency that is comparable to that of
the proposed approach by splitting overlapping subjects
such that the case/control ratios are the same among all
studies. For comparing odds ratios among studies, however,
splitting overlapping subjects is always less efﬁcient than
the proposed approach. As demonstrated in Figure 1 and
Figure 2, the results of meta-analysis may depend appre-
ciably on how overlapping subjects are split. In addition,
the splittingmay need to be redone if new studies are added
or cross-disorder comparisons are to bemade. Furthermore,
splitting control samples requires access to individual
participant data, which are often difﬁcult to obtain, and
tends to induce biases in the presence of plate effects.ber 11, 2009
Overlapping subjects may be genotyped multiple times
with the same or different GWAS platforms. Some of the
NIMH Gejman controls have been genotyped four times,
and the WTCCC controls have been genotyped at least
twice. For the proposed approach, it is implicitly assumed
that each study uses its own genotype calls. For the results
shown in Figure 2, we used the genotype values from the
CATIE study for the CATIE subjects and the genotype
values from the GAIN study for the GAIN subjects. This
strategy avoids the arbitrariness in deciding which set of
genotypes to use and reduces the biases caused by (differ-
ential) measurement errors in case-control comparisons,
especially if cases and controls were randomly assigned
to genotyping plates.
Appendix
Meta-Analysis of Individual Participant Data
We adopt the notation of the main text. Because the mean
of the estimating function U(q) is 0, the corresponding esti-
mator q^ is consistent for q. By the multivariate central limit
theorem, n1/2U(q) is asymptotically zero-mean normal
with covariance matrix
B ¼ limn1
(Xn
i¼1
UiðqÞUiðqÞTþ
Xn
i¼1
Xn
j¼1
dijUiðqÞUjðqÞT
)
,
where the limit is taken as n tends to N. It then follows
from the Taylor series expansion that n1=2ðq^ qÞ is
asymptotically zero-mean normal with covariance
matrix A1B A1, where A ¼ limn1IðqÞ. It is easy to
show that limn1
Pn
i¼1 UiðqÞUiðqÞT ¼ limn1IðqÞ. Thus,
B ¼ limn1 IðqÞ þDðqÞgf . Hence, the asymptotic covari-
ance matrix of n1=2ðq^ qÞ can be consistently estimated
by nI1ðq^ÞfIðq^Þ þDðq^ÞgI1ðq^Þ.
Although the main text of this article was focused on
logistic regression models for case-control studies, the
above derivations are very general, and the results apply
to any phenotypes and any parametric models. The
speciﬁc expressions for the Ui(q)s and I(q) are model depen-
dent.
Meta-Analysis of Summary Results
The original data consist of (Yki,Xki) (i¼ 1,., nk;k¼ 1,., K),
where Yki and Xki are the disease status and the set of
explanatory variables on the ith subject of the kth study.
For the kth study, we ﬁt the following logistic regression
model:
PrðYki ¼ 1 jXkiÞ ¼ e
akþbTkXki
1þ eakþbTk Xki
,
where ak and bk are the intercept and regression parame-
ters. Denote the collection of ak and bk by qk. The
maximum likelihood estimator of qk, denoted by q^k, is
the root of the score functionThe AmericanUkðqkÞ ¼
Xnk
i¼1
 
Yki  e
akþbTk Xki
1þ eakþbTk Xki
!
~Xki,
where ~X consists of 1 and X. By the maximum likelihood
theory, q^k is approximately normal with mean qk and
covariance matrix Ik
1(qk), where
IkðqkÞ ¼
Xnk
i¼1
eakþb
T
k
Xki
ð1þ eakþbTk XkiÞ2
~Xki ~X
T
ki:
By theTaylor series expansion, q^k  qkzI1k ðqkÞUkðqkÞ. Thus,
Cov

q^k,q^l

zI1k ðqkÞCovfUkðqkÞ,UlðqlÞgI1l ðqlÞ:
It is easy to show that
CovfUkðqkÞ,UlðqlÞgz
Xnkl
i¼1
 
Yki  e
akþbTk Xki
1þ eakþbTkXki
!
3
 
Yli  e
alþbTl Xli
1þ ealþbTl Xli
!
~Xki ~X
T
li,
where nkl denotes the number of subjects who overlap
between the kth and lth studies. (Without loss of generality,
we arrange the data such that the ﬁrst nkl records pertain to
the overlapping subjects.) Assume that the disease status is
independent of all explanatory variables such that bk ¼ 0
(k ¼ 1, ., K) and that any subject who appears in more
than one study has the same disease status and same values
of the explanatory variables across studies such thatYki¼Yli
and Xki ¼ Xli for the nkl overlapping subjects. Then
IkðqkÞ ¼ nke
ak
ð1þ eakÞ2n
1
k
Xnk
i¼1
~Xki ~X
T
ki;
therefore,
IkðqkÞz nke
ak
ð1þ eakÞ2H,
where H is the expectation of ~X~XT. By similar arguments,
CovfUkðqkÞ,UlðqlÞgz nkl0e
akþal þ nkl1
ð1þ eakÞð1þ ealÞH:
Thus,
Cov

q^k,q^l

z

nkl0 þ nkl1
eakþal
ð1þ eakÞð1þ ealÞ
nknl
H1:
It follows that the correlation between the same compo-
nents of q^k and q^l is
nkl0
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
eakþal
p
þ nkl1ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
eakþal
p

 ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
nknl
p
:
Note that eakþalznk1nl1=ðnk0nl0Þ.
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Web Resources
The URLs for data presented herein are as follows:
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.
nlm.nih.gov/Omim/ (for T1D, T2D, RA, and schizophrenia)
Software implementing the new methods, http://www.bios.unc.
edu/~lin/software/MAOS/
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